Skip to contentE
ENDRA Life Sciences Inc.
E
NDRAENDRA Life Sciences Inc. Q3 2021 · 10-Q
Revenue—
Net Income-$2.66M-$2.66MN/M vs Q3 2020 EPS Diluted-$0.06-$0.06N/M vs Q3 2020 Operating Income-$2,650,735N/M Operating Cash Flowderived-$2,746,763N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ENDRA Life Sciences Inc. · CIK 1681682 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,746,763N/M ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end